PMS2 and malignant colon neoplasm: Future studies using one or both of these assays to test patients with colon cancers characterized by isolated loss of PMS2 expression and with negative results at first-line mutation analysis will shed light on the true frequency of this deleterious hybrid allele and the possibility that it represents a founder mutation in the population inhabiting the eastern Alpine valleys of Italy (where patient TR13 comes from).